MK2 inhibitors and uses thereof

A compound of formula III:

• or a pharmaceutically acceptable salt thereof, wherein:
• T is —NH— or —O—;
• each R is independently hydrogen or an optionally substituted C1-6 aliphatic, or:
• two R groups on the same nitrogen are taken together with the nitrogen to form a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur;
• R1 is methyl;
• R2 is halogen, —CN, —SRy, —S(O)Ry, —SO2Ry, —OSO2Ry, —OC(O)Ry, or —OP(O)2ORy;
• each Ry is independently selected from optionally substituted C1-6 aliphatic or optionally substituted phenyl;
• R3 is hydrogen, optionally substituted C1-6 aliphatic, —CN, —NO2, halogen, —OR, —N(R)2, —C(O)N(R)2, —C(O)OR, -Cy, —C(O)N(R)-Cy, —C(O)-Cy, —O-Cy, —O—(CH2)n-Cy, —(CH2)n—O-Cy, —N(R)-Cy, —N(R)—(CH2)n-Cy, —(CH2)n—N(R)-Cy, or —(CH2)m-Cy;
• each of m and n is independently 0-4;
• and
• each Cy is independently an optionally substituted ring selected from a 3-9 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 3-9 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, phenyl, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated fused or bridged bicyclic carbocyclic ring, or a 7-12 membered saturated or partially unsaturated fused or bridged bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.